Back to Search
Start Over
CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Source :
- Annals of Surgical Oncology. 23:936-942
- Publication Year :
- 2015
- Publisher :
- Springer Science and Business Media LLC, 2015.
-
Abstract
- CXCL10, a member of the CXC chemokine family, is known to mediate chemotaxis, apoptosis, angiogenesis, and cell growth. It is also reportedly involved in tumor development and can affect prognosis in several cancers. However, the precise relationship between CXCL10 and the prognosis of patients with esophageal squamous cell carcinoma (ESCC) is not fully understood. We used ESCC tissue microarrays containing samples from 177 patients to test whether the CXCL10 expression status, determined using immunohistochemical analysis, is predictive of prognosis. We also tested whether CXCL10 expression status could serve as a clinically useful marker for evaluating the need for adjuvant chemotherapy after surgery. We found that high CXCL10 expression in clinical samples was an independent prognostic factor and was predictive of a favorable 5-year overall survival and disease-specific survival (p = 0.0102 and 0.0332, respectively). Additionally, no significant difference was detected between patients in the CXCL10-high group treated with surgery alone and those treated with surgery followed by adjuvant chemotherapy. In the CXCL10-low group, on the other hand, patients treated with surgery followed by adjuvant chemotherapy had better 5-year overall survival than those treated with surgery alone. High CXCL10 expression is an independent prognostic factor and has the potential to serve as a clinically useful marker of the need for adjuvant chemotherapy after surgery in patients with advanced thoracic ESCC.
- Subjects :
- Male
0301 basic medicine
Oncology
medicine.medical_specialty
Esophageal Neoplasms
Angiogenesis
medicine.medical_treatment
Immunoenzyme Techniques
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
medicine
Carcinoma
Humans
CXCL10
Neoplasm Invasiveness
Survival rate
Aged
Neoplasm Staging
Tissue microarray
business.industry
Thoracic Neoplasms
Prognosis
medicine.disease
Combined Modality Therapy
Chemokine CXCL10
Esophagectomy
Survival Rate
030104 developmental biology
Lymphatic Metastasis
030220 oncology & carcinogenesis
Carcinoma, Squamous Cell
Immunohistochemistry
Female
Surgery
Neoplasm Recurrence, Local
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 15344681 and 10689265
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- Annals of Surgical Oncology
- Accession number :
- edsair.doi.dedup.....1eea725db7b8f8a7a11ea2a1500ba671